In particular, PTP1B has been studied as potential therapeutic drug target in obesity and insulin resistance, since genetic interruption resulted in resistance to high-fat diet-induced insulin resistance and obesity [9,10]. Here, PTPN1 is linked to obesity due to melanocortin 4 receptor deficiency.